Pantoprazol Stada (Pantoprazole)

Pantoprazol Stada belongs to the proton pump inhibitor class and is indicated for conditions involving excess gastric acid secretion.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal lining.
• Erosive esophagitis: supports regeneration of damaged esophageal tissue.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the disorder.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the parietal cell surface of the stomach lining. By binding irreversibly to this pump, it blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity and providing an environment that allows mucosal healing.

Pantoprazol Stada may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild discomfort often resolving without treatment.
• Diarrhea: loose stools that typically improve with continued therapy.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild cramping or discomfort.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhea.
• Low magnesium levels: muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: signs of hepatic stress.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before initiating therapy with Pantoprazol Stada, consider the following safety measures:

• Assess renal function: adjust use in severe impairment.
• Review liver status: use with caution in hepatic disease.
• Evaluate need for long‑term therapy: weigh benefits against fracture risk.
• Monitor electrolytes: especially magnesium during prolonged treatment.
• Avoid abrupt discontinuation: taper to reduce rebound acid hypersecretion.
• Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Pantoprazol Stada can affect the pharmacokinetics of several co‑administered medicines. Review the following interaction categories:

Major Interactions (Avoid)

• Ketoconazole: reduced absorption due to higher gastric pH.
• Atazanavir: markedly decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR; monitor coagulation.
• Digoxin: possible rise in serum levels.
• Methotrexate (high dose): decreased renal clearance; check levels.